Assembly Biosciences (NASDAQ:ASMB) Full Year 2024 Results
Key Financial Results
- Revenue: US$28.5m (up 298% from FY 2023).
- Net loss: US$40.2m (loss narrowed by 34% from FY 2023).
- US$6.69 loss per share (improved from US$13.38 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Assembly Biosciences Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 2.6%.
Looking ahead, revenue is expected to decline by 58% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.
Performance of the American Biotechs industry.
The company's shares are up 1.4% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Assembly Biosciences has 5 warning signs (and 2 which are potentially serious) we think you should know about.
If you're looking to trade Assembly Biosciences, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ASMB
Assembly Biosciences
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
Excellent balance sheet moderate.
